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Abstract 39	
Background  40	
In bronchiectasis, due to cystic fibrosis (CF) and other causes, airways clearance is one of 41	
the mainstays of management. We conducted a systematic review on airways clearance 42	
using non-pharmacological methods as recommended by international guidelines to 43	
develop recommendations or suggestions to update the 2006 CHEST guideline on cough. 44	
Methods 45	
The systematic search for evidence examined the question, “Is there evidence of 46	
clinically important treatment effects for non-pharmacological therapies in cough 47	
treatment for patients with bronchiectasis?”. Populations selected were all patients with 48	
bronchiectasis due to cystic fibrosis or non-CF bronchiectasis. The interventions explored 49	
were the non-pharmacological airway clearance therapies. The comparison populations 50	
included those on standard therapy or placebo. Clinically important outcomes that were 51	
explored were exacerbation rates, quality of life, hospitalizations and mortality. 52	
Results 53	
In both CF and non-CF bronchiectasis, there were systematic reviews and overviews of 54	
systematic reviews identified. Despite these, there were no large randomized controlled 55	
trials that explored the impact of airways clearance on exacerbation rates, quality of life, 56	
hospitalizations or mortality.  57	
Conclusions 58	
While the cough panel was not able to make recommendations, they have made 59	
consensus based suggestions and provided direction for future studies to fill the gaps in 60	
knowledge.  61	
 62	
Abbreviations: 63	
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CF= cystic fibrosis 64	
 65	
Summary of Suggestions 66	
 67	
1. For children and adults with productive cough due to bronchiectasis related to 68	
any cause, we suggest that they be taught airway clearance techniques by 69	
professionals with advanced training in airways clearance techniques. (Ungraded 70	
Consensus-Based Statement) 71	
 72	
2. For children and adults with productive cough due to bronchiectasis related to 73	
any cause, we suggest that the frequency of airways clearance should be 74	
determined by disease severity and amount of secretions. (Ungraded Consensus-75	
Based Statement) 76	
 77	
3. For children and adults with productive cough due to bronchiectasis related to 78	
any cause, we suggest that airway clearance techniques are individualized as 79	
there are many different techniques. (Ungraded Consensus-Based Statement) 80	
 81	
Remarks: These suggestions are based on clinicians’ expertise in managing non-CF 82	
and CF bronchiectasis because there is a lack of large and/or high quality 83	
randomized controlled trials.  84	
The costs can vary depending on the modality of airways clearance used. In 85	
European studies, the least expensive method, the active cycle breathing technique 86	
(ACBT) with or without postural drainage is used first line.1 Other methods are 87	
considered if there is inability to carry out ACBT with or without postural drainage 88	
or there is a clinical deterioration necessitating alternative airways clearance 89	
techniques. 90	
  91	
 92	
	93	
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Background 95	
 96	
In bronchiectasis due to cystic fibrosis (CF) and other causes, treatment of respiratory 97	
infections and airway clearance techniques are mainstays of management. The aims of 98	
airway clearance are to mobilize secretions from the airways and provide some control of 99	
cough. In clinical practice, there are a variety of techniques: active cycle breathing with 100	
or without the assistance of postural drainage; positive expiratory pressure; flutter-type 101	
devices; airway oscillation; respiratory muscle training; coached coughing; huffing; 102	
cough assist device (insufflation/exsufflation); assisted coughing (e.g., quad coughing); 103	
functional electrical stimulation; high frequency chest wall oscillators and general 104	
exercise. The aims of treatment are to clear the airways of tenacious secretions, reduce 105	
cough and sputum production, improve functional and health status, and reduce the 106	
frequency and/or severity of exacerbations. This expert panel report focuses on airway 107	
clearance as recommended by international guidelines.1-5 We present evidence-based 108	
reviews for the key question developed on using non-pharmacological airway clearance 109	
techniques for the management of people with bronchiectasis, summary of the evidence 110	
and the formulated suggestions based upon these findings utilizing CHEST’s cough 111	
guidelines methods and framework.6 112	
 113	
 114	
Methods 115	
 116	
The	methodology	of	the	CHEST	Guideline	Oversight	Committee6	was	used	to	select	117	
the	 Expert	 Cough	 Panel	 Chair	 and	 the	 international	 panel	 of	 pediatric	 and	 adult	118	
experts	in	non	CF‐bronchiectasis	and	cystic	fibrosis	to	synthesize	the	evidence	and	119	
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to	develop	the	suggestions	that	are	contained	within	this	article.	 In	addition	to	the	120	
quality	 of	 the	 evidence,	 the	 recommendation/suggestion	 grading	 also	 includes	 a	121	
strength	 of	 recommendation	 dimension,	 used	 for	 all	 CHEST	 Guidelines.6	 The	122	
strength	of	recommendation	here	is	based	on	consideration	of	three	factors:	balance	123	
of	benefits	 to	harms,	patient	values	and	preferences,	 and	 resource	considerations.	124	
Harms	incorporate	risks	and	burdens	to	the	patients	that	can	include	convenience	125	
or	lack	of	convenience,	difficulty	of	administration,	and	invasiveness.	These,	in	turn,	126	
impact	patient	preferences.	The	resource	considerations	go	beyond	economics	and	127	
should	also	factor	in	time	and	other	indirect	costs.	The	authors	of	these	suggestions	128	
have	considered	these	parameters	in	determining	the	strength	of	the	suggestions.	129	
	130	
The	 findings	 of	 a	 systematic	 search	 for	 and	 evaluation	 of	 evidence	 were	 used	 to	131	
support	the	evidence	graded	recommendations	or	suggestions.	A	highly‐structured	132	
consensus‐based	 Delphi	 approach	 was	 employed	 to	 provide	 expert	 advice	 on	 all	133	
guidance	 statements.6	 	 The	 total	 number	 of	 eligible	 voters	 for	 each	 guidance	134	
statement	did	not	vary	because	none	were	recused	from	voting	on	any	statements	135	
because	 of	 their	 potential	 conflicts	 of	 interest.	 Transparency	 of	 process	 was	136	
documented.	 Further	 details	 of	 the	 methods	 related	 to	 conflicts	 of	 interests	 and	137	
transparency	for	all	CHEST	guidelines	have	been	previously	published.6	138	
	139	
Based	on	 the	 evidence	 review	and	 the	Delphi	methodology	described,	 the	writing	140	
group	developed	guideline	recommendations	or	suggestions.	These	then	underwent	141	
review	and	voting	by	the	full	cough	panel.	For	a	recommendation	or	suggestion	to	142	
be	 accepted,	 it	 had	 to	 be	 voted	 upon	 by	 75%	 of	 the	 eligible	 Cough	 Panelists	 and	143	
achieve	ratings	of	strongly	agree	or	agree	by	80%	of	the	voting	panelists.	Agreement	144	
was	 achieved	 by	 85‐90%	 of	 those	 voting	 in	 the	 current	 recommendations.	 No	145	
panelist	was	excluded	from	voting.	146	
 147	
Key Question Development 148	
 149	
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A key clinical question (KQ) was developed using the PICO (Population, Intervention, 150	
Comparator, Outcome) format.  The following question was addressed: 151	
“Is there evidence of clinically important treatment effects for non-pharmacological 152	
therapies in cough treatment for patients with bronchiectasis?”  153	
 154	
 155	
Systematic Literature Search 156	
 157	
A systematic literature search for individual studies was initially conducted using the 158	
following databases: MEDLINE via PubMed, EMBASE, and Scopus with date 159	
limitations from database inception through 05/09/13 for non-pharmacological therapies 160	
for airway clearance. Thirty systematic reviews were identified in the Cochrane Library 161	
and 83 in PubMed. Additional searches for trials were conducted in the 2 databases, with 162	
229 identified in PubMed and 319 in the Cochrane Library. The search was updated in 163	
February of 2015 during which time separate searches were conducted for CF and for 164	
non-CF bronchiectasis in PubMed and the Cochrane Library. During this extended search, 165	
a total of 194 citations were retrieved for CF and 113 for non-CF bronchiectasis.  To be 166	
certain that the most current versions of Cochrane reviews were used to inform the 167	
evidence, another search of the PubMed and Cochrane databases were performed on May 168	
3, 2016. One update of an included Cochrane systematic review and five new systematic 169	
reviews were discovered while no newer primary studies were identified through this 170	
search. (PRISMA flow chart- Figure 1). 171	
 172	
Using dual review, four panelists independently reviewed the titles and abstracts of the 173	
search results to identify potentially relevant articles based on the inclusion and exclusion 174	
criteria.  Discrepancies were resolved by discussion.  Studies deemed eligible then 175	
underwent a second round of full-text screening for final inclusion.  Important data from 176	
each included study were then extracted into structured evidence tables. (See 177	
Supplement) In each step, dual review and dual extraction were performed. 178	
 179	
Quality assessment   180	
9	
	
  181	
The identified systematic reviews were assessed for quality and risk of bias using the 182	
Documentation and Appraisal Tool For Systematic Reviews (DART).7   183	
 184	
 185	
Peer Review Process 186	
 187	
The manuscript went through 2 rounds of review.  During the first round, identified 188	
reviewers from the Guidelines Oversight Committee (GOC) of the CHEST Organization 189	
reviewed the content and methods of the manuscript for consistency, accuracy and 190	
completeness.  The manuscript was revised after consideration by the panel of the 191	
feedback received from the GOC reviewers and then submitted to the CHEST journal for 192	
review by a representative from the CHEST Board of Regents, 1 of the 4 CHEST 193	
Presidents and journal-identified reviewers.  194	
 195	
PICO Question Development 196	
 197	
Initially, the key question was phrased as “Is there evidence of clinically relevant 198	
treatment effects for non-pharmacological therapies in cough treatment for patients with 199	
diseases that affect airway clearance and ineffective cough?” During the review process, 200	
the panel decided to substitute the word “important” for “relevant,” eliminate the phrase 201	
“ineffective cough” and to focus on bronchiectasis. The initial search included the term 202	
ineffective cough, however the subsequent searches did not. 203	
 204	
The interventions included were the following non-pharmacological airway clearance 205	
therapies: positive expiratory pressure; vibrating vest; flutter-type devices; airway 206	
oscillation; conventional chest physiotherapy and postural drainage; respiratory muscle 207	
training; coached coughing (having patients start coughing at total lung capacity); 208	
huffing; cough assist device (insufflation/exsufflation); assisted coughing (quad 209	
coughing); functional electrical stimulation; and abdominal binders. The comparison 210	
10	
	
populations were on standard therapy and/or placebo. Clinically important outcomes that 211	
were assessed were exacerbation rates, quality of life, hospitalizations and mortality. 212	
 213	
 214	
RESULTS: 215	
 216	
Summary and Interpretation of the evidence for non-CF bronchiectasis. 217	
After full text review by panelists and the methodologist, no primary studies met all 218	
criteria described under the section PICO question development.  An updated search 219	
performed on 5/3/16 after full text review identified a good quality Cochrane overview of 220	
systematic reviews on the topic of pharmacological and non-pharmacological 221	
interventions for bronchiectasis.8		Overviews	of	systematic	reviews	are	a	relatively	222	
new	study	design	included	in	the	Cochrane	Handbook	for	Systematic	Reviews	of	223	
Interventions.9	Overviews	of	Systematic	Reviews	compile	evidence	from	multiple	224	
systematic	reviews	on	an	intervention	into	a	single	summary	document.	They	are	225	
conducted	following	systematic	and	rigorous	methods	similar	to	systematic	reviews,	226	
but	include	systematic	reviews	rather	than	primary	studies. 227	
 228	
The overview identified 9 eligible systematic reviews for the topic that included 229	
pharmacological therapies. Of these 9, only 4 examined non-pharmacological methods.  230	
One of the 4 was on singing and another compared nurse to doctor led care. Two good 231	
quality systematic reviews examining the effectiveness of non-pharmacological airway 232	
clearance therapies remained. One of these reviews10 evaluated an airway clearance 233	
technique that used a twice-daily oscillatory Positive Expiratory Pressure (PEP) device in 234	
one very small study of 20 adult subjects. This was a cross over study that compared 3 235	
months of treatment using an Acapella PEP device versus no chest physiotherapy in 236	
patients that admitted not practicing regular airway clearance.11 In addition to being very 237	
small, the single study was assessed by the systematic review authors as having a high 238	
risk of bias. This leads to an overall assessment of very low quality for the finding of 239	
non-significant reduction in exacerbations.  The review also evaluated quality of life but 240	
11	
	
did not report confidence intervals around the mean difference so that significance could 241	
not be assessed. Hospitalization and mortality were not assessed in this study. The 242	
updated search for Cochrane systematic reviews did discover an update of this systematic 243	
review in 2015. However, the updated systematic review did not identify any new 244	
primary studies that evaluated the clinically important outcomes we specified.  245	
 246	
The second systematic review evaluated physical training using Inspiratory Muscle 247	
Training compared to no or sham therapy.  This review identified 2 eligible trials with a 248	
combined total of only 43 subjects.12 The authors of the overview also described  249	
additional small studies not included in the Bradley systematic review in their evidence 250	
map. One, a small study in 32 patients showed that the positive training benefits with 251	
pulmonary rehabilitation are maintained with adjunct of inspiratory muscle training.13 A 252	
further study in 26 patients showed no quality of life improvement despite improved 253	
respiratory muscle strength.14 The systematic review measured quality of life using the 254	
Chronic Respiratory Disease Questionnaire.15 The authors reported major deficiencies in 255	
the primary studies including no description of randomization, no summary of findings, 256	
blinding was not possible, the subject groups differed at study start, and the total Jadad 257	
quality score was only 1/5.  In summary, the 2 very small trials included in the second 258	
systematic review had high risk of bias. This leads to an overall assessment of very low 259	
quality and very low confidence in any findings. Therefore, no reliable evidence for non-260	
pharmacological techniques to improve clinically important outcomes in non-CF 261	
bronchiectasis was identified.   262	
 263	
Our findings are dissimilar to the most recent Cochrane review10 on this subject since 264	
only one of the seven studies in the Cochrane review met all our inclusion criteria. 265	
 266	
Discussion 267	
 268	
There is a lack of large and/or high quality trials that address the clinically important 269	
outcomes of exacerbation rates, quality of life, hospitalizations or mortality. The absence 270	
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of high quality evidence does not imply that efforts to assist airways clearance be 271	
abandoned since it is a standard component of the management of bronchiectasis. 272	
 273	
Summary and Interpretation of the evidence for CF bronchiectasis.  274	
After full text review by panelists and the methodologist, no primary studies met all 275	
criteria described under the section PICO question development.  Four Cochrane 276	
systematic reviews were identified. An updated search performed on 5/3/16 after full text 277	
review of the primary studies and specifically focusing on systematic reviews identified 278	
two updates of the Cochrane systematic reviews and three additional Cochrane 279	
systematic reviews on various non-pharmacological interventions for cystic fibrosis. Of 280	
those 7 total systematic reviews identified, only 5 reported on the clinically important 281	
outcomes of mortality, hospitalizations, exacerbations and quality of life and these were 282	
of good quality. 283	
 284	
The 5 systematic reviews examined the following interventions: 285	
o Positive Expiratory Pressure (PEP) compared to Conventional Chest 286	
Physiotherapy Techniques (CCPT).  287	
o Positive Expiratory Pressure (PEP) compared to oscillating devices. 288	
o Various Forced Expiration Techniques (FET) and Conventional Chest 289	
Physiotherapy Techniques (CCPT) comparisons. 290	
o Inspiratory muscle training methods (IMT) compared to each other, to no or sham 291	
methods.  292	
 293	
A Cochrane review by Main et al16 compared Conventional Chest Physiotherapy 294	
Techniques (CCPT) with other airway clearance techniques and examined some 295	
clinically important outcomes.  One study of 61 subjects examined quality of life, 2 296	
studies of 79 subjects examined number of hospital days and 2 studies of 99 subjects 297	
examined number of admissions per year. For quality of life, 1 study was available as an 298	
abstract only so the authors report unclear risk of bias and a low-quality score (2/5 Jadad). 299	
Data were not reported, only the overall finding of no difference between CCPT and PEP.  300	
For number of hospital days, 1 small study of 16 subjects comparing CCPT to Airway 301	
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Oscillating Devices (AOD) was available as abstract only so no quality assessment was 302	
performed. The range of values for the mean difference was broad, finding no significant 303	
difference. The study of 63 subjects comparing CCPT to Active Cycle of Breathing 304	
Techniques (ACBT)/Forced Expiration Technique (FET) did not report data. For number 305	
of admissions per year, one study of 36 subjects compared CCPT to Positive Expiratory 306	
Pressure (PEP) and the other study of 63 subjects compared CCPT to ACBT/FET. 307	
Neither study found a significant difference between methods. The inability to evaluate 308	
whether any newer techniques are better than CCPT in cystic fibrosis is due to 309	
insufficient data. 310	
 311	
A Cochrane review by McIlwaine et al17 compared PEP to oscillating devices and 312	
evaluated the outcome of exacerbations. Four studies were examined and data were 313	
analyzed for 2 studies that were both rated as having low risk of bias by the reviewing 314	
authors. One study of 88 subjects over 1 year found a significant reduction in 315	
exacerbations for PEP compared to high frequency chest wall oscillation (HFCWO) RR= 316	
0.73 (95% CI 0.55-0.95). The mean number of pulmonary exacerbations were 1.14 for 317	
PEP vs. 2.0 for HFCWO and time to first pulmonary exacerbation was 220 days for PEP 318	
vs. 115 days for HFCWO, p=0.02.18 The study of PEP vs. oscillating PEP included 41 319	
subjects and found no significant difference.  320	
 321	
A Cochrane review by McKoy19 compared FET (active cycle breathing technique) to 322	
CCPT + FET for the outcome of exacerbations. One prospective study of 63 subjects 323	
over 3 years was included that suffered from unclear allocation concealment and blinding 324	
was not possible. There was 6% loss to follow-up and no intention to treat analysis. There 325	
was no significant difference between treatments, with 9 out of 31 patients receiving FET 326	
and 5 of 30 receiving CCPT + FET experiencing exacerbations RR = 1.64 (95% CI 0.62-327	
4.34). 328	
 329	
A Cochrane review by Morrison20 compared oscillatory devices to PEP for the outcomes 330	
of quality of life, exacerbations and number and days of hospitalizations. For quality of 331	
life that was assessed using Quality of Well-being Scale (QWBS) or Chronic Respiratory 332	
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Disease Questionnaire (CRDQ), there were 2 studies of 88 and 43 subjects that reported 333	
data. One study had an early dropout rate of nearly 20% and in the other the groups 334	
differed at study start. There was no significant difference in quality of life between the 335	
groups. For exacerbations, one study of 88 subjects reported data. This study had an early 336	
dropout rate of nearly 20%. The study reported an increase in the requirement of 337	
antibiotics for exacerbations OR = 4.10 (1.42 - 11.84) for oscillation devices compared to 338	
PEP. This is the same study reported in the review by McIlwaine (see above). For 339	
number of hospitalizations, 1 study of 42 subjects found no significant difference 340	
between groups. For days of hospitalization, 3 studies of 86 total subjects comparing 341	
oscillation devices to CCPT were all reported to suffer from high risk of bias.  There 342	
were no significant differences between groups. 343	
 344	
A Cochrane review by Houston et al21 examined inspiratory muscle training (IMT) as 345	
achieved by voluntary isocapnic hyperpnea, resistive loading or threshold loading 346	
compared with each other or with none or sham. Only 2 studies with a total of 180 adult 347	
subjects with CF were included. Both studies were poorly reported (1 was only available 348	
as an abstract) and the authors rated the studies at high risk of bias. Quality of life was 349	
assessed but no outcome data reported. The authors concluded that they didn’t find any 350	
evidence to suggest that the treatment was either beneficial or not and they advised that 351	
practitioners evaluate on a case-by-case basis whether or not to employ this therapy. 352	
 353	
While the systematic reviews were of good quality, most of the individual studies were 354	
not. All studies were small and were likely underpowered and provided insufficient data 355	
to identify differences between groups.  356	
 357	
Only one primary study included in the 5 systematic reviews reported any significant 358	
differences between groups. That study, McIlwaine and colleagues, compared high 359	
frequency chest wall oscillation (HFCWO) to PEP in 88 analyzed subjects.18 It was 360	
reported as being at low risk of bias and found an increase in exacerbations in subjects 361	
using HFCWO compared to those using PEP. 362	
 363	
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In summary, there is insufficient evidence that any airway clearance technique is 364	
consistently more effective than any other for clinically important outcomes in CF 365	
bronchiectasis. The absence of high quality evidence does not imply that efforts to assist 366	
airways clearance be abandoned since it is a standard component of the management of 367	
CF. 368	
 369	
Summary of Suggestions 370	
1. For children and adults with productive cough due to bronchiectasis related to 371	
any cause, we suggest that they be taught airway clearance techniques by 372	
professionals with advanced training in airways clearance techniques. (Ungraded 373	
Consensus-Based Statement) 374	
 375	
2. For children and adults with productive cough due to bronchiectasis related to 376	
any cause, we suggest that the frequency of airways clearance should be 377	
determined by disease severity and amount of secretions. (Ungraded Consensus-378	
Based Statement) 379	
 380	
3. For children and adults with productive cough due to bronchiectasis related to 381	
any cause, we suggest that airway clearance techniques are individualized as 382	
there are many different techniques. (Ungraded Consensus-Based Statement) 383	
 384	
Remarks: These suggestions are based on clinicians’ expertise in managing non-CF 385	
and CF bronchiectasis because there is a lack of large and/or high quality 386	
randomized controlled trials.  387	
The costs can vary depending on the modality of airways clearance used. In 388	
European studies, the least expensive method, the active cycle breathing technique 389	
(ACBT) with or without postural drainage is used first line.1 Other methods are 390	
considered if there is inability to carry out ACBT with or without postural drainage 391	
or there is a clinical deterioration necessitating alternative airways clearance 392	
techniques. 393	
 394	
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  395	
 396	
  397	
 398	
Areas of Future Research: 399	
Airways clearance research in bronchiectasis due to CF or non-CF bronchiectasis has 400	
been underwhelming due to the lack of adequately powered randomized controlled trials. 401	
These trials are challenging as ideally the comparator arm would be no physiotherapy, 402	
making the studies challenging to blind and leading to ethical challenges, due to airway 403	
clearance being regarded as standard care. This has led to under-powered comparator 404	
studies of one technique versus another technique. Future studies assessing the optimum 405	
method, duration and frequency for long term (more than 28 days) airways clearance with  406	
clinical important outcomes are needed as well as the optimum target group.  407	
 408	
To advance the field, there are several potential research endeavors that should be 409	
undertaken. They are enumerated here: 410	
1] To determine the clinically meaningful role of any non-pharmacological airway 411	
clearance modality, clinically important outcomes such as exacerbation rate, 412	
hospitalization rate, quality of life using	an	instrument	validated	in	CF	and/or	413	
bronchiectasis, or mortality should be targeted as primary outcomes in future studies. 414	
2] Does regular daily airway clearance improve outcomes (e.g. reduce the duration and 415	
frequency of exacerbations, improve QoL) in children and adults with non-CF and CF 416	
bronchiectasis? 417	
3] What is the optimum method for long term (more than 28 days) airways clearance in 418	
children and adults with non-CF and CF bronchiectasis that will lead to meaningful 419	
clinical outcomes? 420	
4] What is the optimum duration and frequency for daily long term (more than 28 days) 421	
airways clearance in children and adults with non-CF and CF bronchiectasis that will lead 422	
to meaningful clinical outcomes? 423	
17	
	
5] What target group(s) among children and adults with CF and non-CF bronchiectasis 424	
will benefit in meaningful clinical outcomes from airway clearance considering severity 425	
of bronchiectasis, frequency of exacerbations and comorbidities? 426	
 427	
Conclusion: 428	
 429	
Since publication of the 2006 CHEST Cough Guidelines,4 the effect of non-430	
pharmacological airway clearance techniques on meaningful clinical outcomes in non-CF 431	
and CF bronchiectasis such as rates of exacerbations, hospitalizations, quality of life and 432	
mortality is still not known. The systematic review portion of this article has identified 433	
gaps in our knowledge and areas for future research. Just as stated in the 2006 guidelines, 434	
a plea is again made that clinically important outcomes should be targeted as primary 435	
outcomes in future studies to determine the meaningful role of non-pharmacological 436	
airway clearance modalities. 437	
 438	
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Figure 1: PRISMA flow chart PRISMA Flow Chart for Non-Pharmacological 564	
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